Transgene (TNG FP) France
Report by Intron Health
With BT-001 advancing into phase I trials, TNG now has four oncology assets in clinical development and multiple important catalysts in the coming 12 months. TG4001 has started phase II, TG6002 reported first positive human data in April with a further readout in Q4 and most importantly, TG4050 is expected to report an immunological readout in Q4 which could demonstrate proof-of-concept for the technology. The company has financial runway to the end of FY23. Intron’s SOTP values TNG at €3.20/share (40% upside).